PD-L1与STAT1在弥漫性大B细胞淋巴瘤中的表达及预后研究OA
The expression and prognosis of PD-L1 and STAT1 in diffuse large B-cell lymphoma
本研究旨在探究PD-L1 与STAT1在弥漫大 B 细胞淋巴瘤(DLBCL)中的表达情况及相关性,评估其与DLBCL 患者临床病理特征及预后的关系.利用 GEPIA 和 GEO数据库分析 DLBCL 组织中PD-L1 和 STAT1的表达水平.通过免疫组织化学检测 72例 DLBCL 患者肿瘤组织中 PD-L1 和 STAT1的蛋白表达水平,并收集其临床资料,结合生存分析和多因素 Cox回归分析验证 PD-L1 和 STAT1在 DLBCL 中的预后价值.GEPIA、GEO 差异分析与免疫组织化学检测结果一致显示,PD-L1 和 STAT1在DLBCL 中均显著高表达(P<0.05).在 72例 DLBCL患者中,PD-L1、STAT1及两者共表达的阳性率分别为 69.44%、77.78%和 56.94%.PD-L1与 STAT1表达呈显著正相关(r=0.256 7,P=0.029 5),此外,PD-L1/STAT1共表达与 DLBCL 患者的预后也呈显著关联(P<0.001).多因素Cox回归分析进一步显示,PD-L1和STAT1阳性表达在OS和PFS分析中仍为独立危险因素(PD-L1:OS/PFS均 P<0.001;STAT1:OS P=0.032,PFSP=0.014).本研究证实 PD-L1 与 STAT1 在DLBCL 中协同高表达,其单独阳性表达及共表达状态可作为评估 DLBCL 患者预后的独立分子标志物,提示 PD-L1 与 STAT1 有望成为DLBCL 潜在治疗靶点,为临床开展个体化预后分层评估及制定靶向治疗策略提供重要的参考依据.
This study aims to investigate the expression and correlation of PD-L1 and STAT1 in DLBCL,and to evaluate their association with the clinicopathological features and prognosis of DLBCL patients.The transcriptional expression profiles of PD-L1 and STAT1 in DLBCL tissues were analyzed using the GEPIA and GEO public databases.Additionally,immunohistochemistry was performed to detect the protein expression of PD-L1 and STAT1 in tumor tissues from 72 DLBCL patients,whose clinical data were also collected.Combined with the survival analysis and multivariate Cox regression analysis,these data were used to validate the prognostic value of PD-L1 and STAT1 in DLBCL.Consistent results across GEPIA,GEO,and immunohistochemical cohorts uniformly showed that both PD-L1 and STAT1 were significantly upregulated in DLBCL tissues(P<0.05).Among the 72 DLBCL patients,the positive expression rates of PD-L1,STAT1,and PD-L1/STAT1 co-expression were 69.44%,77.78%,and 56.94%,respectively.PD-L1 expression was positively correlated with STAT1 expression(r=0.256 7,P=0.029 5).Moreover,PD-L1/STAT1 co-expression was significantly associated with poor prognosis in DLBCL patients(P<0.001).Further multivariate Cox regression analysis showed that positive expression of PD-L1 and STAT1 remained independent adverse risk factors for both OS and PFS(PD-L1:P<0.001 for OS and PFS;STAT1:OS,P=0.032;PFS,P=0.014).This study confirms that PD-L1 and STAT1 are co-upregulated in DLBCL,and that their individual positive expression as well as co-expression can serve as independent molecular markers for evaluating the prognosis of DLBCL patients.These findings suggest that PD-L1 and STAT1 may represent potential therapeutic targets for DLBCL,providing important theoretical and experimental support for individualized prognostic stratification and the development of targeted treatment strategies in clinical practice.
王珏;潘云
大理大学基础医学院,云南,大理 671000大理大学第一附属医院病理科,云南,大理 671000
生物科学
PD-L1STAT1弥漫性大B细胞淋巴瘤相关性分析
PD-L1STAT1diffuse large B-cell lymphomacorrelation analysis
《井冈山大学学报(自然科学版)》 2026 (5)
55-68,14
国家自然科学基金项目(82160044)云南省教育厅科研基金项目(2025Y1196)
评论